MA46673A - Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 - Google Patents
Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1Info
- Publication number
- MA46673A MA46673A MA046673A MA46673A MA46673A MA 46673 A MA46673 A MA 46673A MA 046673 A MA046673 A MA 046673A MA 46673 A MA46673 A MA 46673A MA 46673 A MA46673 A MA 46673A
- Authority
- MA
- Morocco
- Prior art keywords
- dkk
- catenin
- biomarker
- antibody
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413198P | 2016-10-26 | 2016-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46673A true MA46673A (fr) | 2019-09-04 |
Family
ID=60570180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046673A MA46673A (fr) | 2016-10-26 | 2017-10-26 | Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11267876B2 (https=) |
| EP (1) | EP3532099A1 (https=) |
| JP (2) | JP7374765B2 (https=) |
| KR (1) | KR102701695B1 (https=) |
| CN (1) | CN110114087A (https=) |
| AU (1) | AU2017347822B2 (https=) |
| BR (1) | BR112019008279A2 (https=) |
| CA (1) | CA3041325A1 (https=) |
| IL (1) | IL266199B2 (https=) |
| MA (1) | MA46673A (https=) |
| MX (1) | MX2019004940A (https=) |
| RU (1) | RU2019115946A (https=) |
| SG (1) | SG11201903602RA (https=) |
| WO (1) | WO2018081437A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102701695B1 (ko) | 2016-10-26 | 2024-08-30 | 리프 테라퓨틱스 인코포레이티드 | 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 |
| CA3128526A1 (en) | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
| BR112022004851A2 (pt) * | 2019-09-19 | 2022-08-23 | Leap Therapeutics Inc | Uso de inibidores de dkk-1 para tratar câncer |
| EP4061419A1 (en) * | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| EP4471056A4 (en) | 2022-01-28 | 2026-02-18 | Shanghai Junshi Biosciences Co Ltd | Anti-DKK1 antibodies, pharmaceutical composition and associated uses |
| US20250222062A1 (en) * | 2022-03-24 | 2025-07-10 | The Translational Genomics Research Institute | Peptide inhibitors targeting the tbl1-beta-catenin complex |
| CN116350758B (zh) * | 2023-03-16 | 2024-08-06 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7446181B2 (en) * | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| CN101641373B (zh) * | 2007-02-08 | 2015-02-11 | 默沙东公司 | Dkk-1的特异性抗体 |
| WO2009028158A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| CN102421798A (zh) | 2009-05-07 | 2012-04-18 | 诺瓦提斯公司 | 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法 |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CN103608037B (zh) * | 2011-02-01 | 2016-04-13 | 香港大学 | 抗dkk1单克隆抗体用于治疗肝癌的用途 |
| ES2703208T3 (es) * | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
| TW201610168A (zh) * | 2013-12-02 | 2016-03-16 | 安可美德藥物股份有限公司 | 與Ｗｎｔ途徑抑制劑有關之預測性生物標記之鑑別 |
| KR102701695B1 (ko) | 2016-10-26 | 2024-08-30 | 리프 테라퓨틱스 인코포레이티드 | 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 |
| BR112022004851A2 (pt) | 2019-09-19 | 2022-08-23 | Leap Therapeutics Inc | Uso de inibidores de dkk-1 para tratar câncer |
| EP4061419A1 (en) | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
| KR20250057775A (ko) | 2022-07-12 | 2025-04-29 | 리프 테라퓨틱스 인코포레이티드 | 조합 요법 |
-
2017
- 2017-10-26 KR KR1020197014600A patent/KR102701695B1/ko active Active
- 2017-10-26 WO PCT/US2017/058555 patent/WO2018081437A1/en not_active Ceased
- 2017-10-26 CA CA3041325A patent/CA3041325A1/en active Pending
- 2017-10-26 IL IL266199A patent/IL266199B2/en unknown
- 2017-10-26 AU AU2017347822A patent/AU2017347822B2/en active Active
- 2017-10-26 SG SG11201903602RA patent/SG11201903602RA/en unknown
- 2017-10-26 MX MX2019004940A patent/MX2019004940A/es unknown
- 2017-10-26 CN CN201780071597.0A patent/CN110114087A/zh active Pending
- 2017-10-26 MA MA046673A patent/MA46673A/fr unknown
- 2017-10-26 US US16/345,191 patent/US11267876B2/en active Active
- 2017-10-26 JP JP2019522823A patent/JP7374765B2/ja active Active
- 2017-10-26 BR BR112019008279-4A patent/BR112019008279A2/pt active Search and Examination
- 2017-10-26 RU RU2019115946A patent/RU2019115946A/ru unknown
- 2017-10-26 EP EP17808633.6A patent/EP3532099A1/en active Pending
-
2022
- 2022-01-28 US US17/587,708 patent/US12319730B2/en active Active
-
2023
- 2023-07-26 JP JP2023121862A patent/JP2023133432A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018081437A1 (en) | 2018-05-03 |
| CA3041325A1 (en) | 2018-05-03 |
| JP7374765B2 (ja) | 2023-11-07 |
| KR20190085935A (ko) | 2019-07-19 |
| SG11201903602RA (en) | 2019-05-30 |
| RU2019115946A (ru) | 2020-11-27 |
| EP3532099A1 (en) | 2019-09-04 |
| US12319730B2 (en) | 2025-06-03 |
| IL266199B1 (en) | 2024-10-01 |
| AU2017347822A1 (en) | 2019-05-09 |
| AU2017347822B2 (en) | 2025-01-16 |
| RU2019115946A3 (https=) | 2021-01-26 |
| US20220289831A1 (en) | 2022-09-15 |
| JP2023133432A (ja) | 2023-09-22 |
| IL266199B2 (en) | 2025-02-01 |
| CN110114087A (zh) | 2019-08-09 |
| MX2019004940A (es) | 2019-09-26 |
| KR102701695B1 (ko) | 2024-08-30 |
| US20190284264A1 (en) | 2019-09-19 |
| BR112019008279A2 (pt) | 2019-07-09 |
| IL266199A (en) | 2019-06-30 |
| JP2019533693A (ja) | 2019-11-21 |
| US11267876B2 (en) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46673A (fr) | Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 | |
| MA53338A (fr) | Dosages pour détecter la neurodégénérescence | |
| MA48604A (fr) | Anticorps anti-tim-3 pour une combinaison avec des anticorps anti-pd-1 | |
| MA46952A (fr) | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet | |
| EP3714275A4 (en) | REDUCTION OF CONNECTING EPITOPES FOR NEOANTIGENS | |
| SG11201606291VA (en) | Assays for detecting the presence or amount of an anti-drug antibody | |
| EP3359573A4 (en) | MARKING OF ANTIBODIES | |
| EP3503920A4 (en) | ANTI-CTLA4 ANTIBODIES | |
| MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EP3507307A4 (en) | BISPECIFIC ANTIBODIES | |
| EP3717916C0 (en) | TARGET INTERFERENCE SUPPRESSION ANTI-DRUG ANTIBODY ASSAY | |
| MA45687A (fr) | 99mtc-edda/hynic-ipsma à utiliser en tant que radiopharmaceutique pour détecter la surexpression de l'antigène membranaire spécifique de la prostate | |
| MA49377A (fr) | Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë | |
| EP3376229A4 (en) | BIOMARKERS FOR THE DIAGNOSIS OF DEPRESSIONS AND THE USE OF THE BIOMARKER | |
| EP3492591A4 (en) | ANTI-B7-H4 ANTIBODIES | |
| EP3384035A4 (en) | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES | |
| EP3399992A4 (en) | SELF-NETWORKING ANTIBODIES | |
| EP3484919A4 (en) | ANTIBODIES AGAINST AMYLOID BETA | |
| EP3493819A4 (en) | Keratin 17 as an organic marker for bladder cancer | |
| EP3397262A4 (en) | COMBINATION OF AN HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF EGG CANCER | |
| FR3047674B1 (fr) | Utilisation d'amines alkoxylees en tant qu'agents collecteurs pour l'enrichissement de minerai | |
| EP3397360A4 (en) | PEDAL ARRANGEMENT FOR EXERCISE MACHINE | |
| EP3582683A4 (en) | SEROLOGICAL TEST FOR SILENT BRAIN ISEMIA | |
| MA42706A (fr) | Anticorps et dosages pour la détection de cd37 | |
| EP2877855A4 (en) | MULTISIGNAL REAGENTS FOR MARKING ANALYTES |